Melanoma
Ipilimumab (Yervoy) 3- vs 10-mg/kg for Metastatic Melanoma
A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg Versus at 10 mg /kg in Subjects With Previously Treated or Untreated Unresectable or Metastatic Melanoma
Investigator: Kim Margolin, M.D.; Conditions: Melanoma; Status: Recruiting; Study ID: NCT01515189
Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node [Randomization phase]
Investigator: David Byrd, MD; Conditions: Melanoma; Status: Recruiting; Study ID: NCT00389571
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Investigator: Kim Margolin, M.D.; Conditions: Malignant Melanoma; Status: Recruiting; Study ID: NCT01378975
The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma
Investigator: Kim Margolin, MD; Conditions: Malignant Melanoma; Status: Recruiting; Study ID: NCT01288963
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery
Investigator: Fred Appelbaum, MD; Conditions: Melanoma; Status: Recruiting; Study ID: NCT01274338
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
Investigator: Scott S. Tykodi, MD, PhD; Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer, Colorectal Adenocarcinoma; Status: Recruiting; Study ID: NCT00729664
A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma
Investigator: Dr. Shailender Bhatia; Conditions: Metastatic Melanoma; Status: Closed/Not Recruiting; Study ID: NCT01011530
Phase I/II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cell Clones and Anti-CTLA4 for Patients With Metastatic Melanoma
Investigator: Aude Chapuis, MD; Conditions: Melanoma (Skin); Status: Recruiting; Study ID: NCT00871481
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma
Investigator: Shailender Bhatia, M.D.; Conditions: Melanoma; Status: Recruiting; Study ID: NCT01489059
Join Us On